Halozyme Therapeutics, Inc. (HALO)
Automate Your Wheel Strategy on HALO
With Tiblio's Option Bot, you can configure your own wheel strategy including HALO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HALO
- Rev/Share 8.8001
- Book/Share 3.9141
- PB 15.3268
- Debt/Equity 3.1257
- CurrentRatio 8.3923
- ROIC 0.2343
- MktCap 7392027790.0
- FreeCF/Share 4.0235
- PFCF 14.9106
- PE 15.2292
- Debt/Assets 0.6863
- DivYield 0
- ROE 1.2224
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | HALO | Goldman | -- | Neutral | -- | $55 | July 10, 2025 |
| Downgrade | HALO | Morgan Stanley | Overweight | Equal Weight | -- | $62 | May 14, 2025 |
| Downgrade | HALO | Leerink Partners | Market Perform | Underperform | -- | $47 | May 13, 2025 |
| Downgrade | HALO | Wells Fargo | Overweight | Equal Weight | $58 | $62 | Oct. 7, 2024 |
| Downgrade | HALO | JP Morgan | Overweight | Neutral | $52 | $57 | Sept. 19, 2024 |
News
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.26 1 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to …
Read More
About Halozyme Therapeutics, Inc. (HALO)
- IPO Date 2004-03-16
- Website https://www.halozyme.com
- Industry Biotechnology
- CEO Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employees 350